“We also expect the full Phase III program readout on our weekly basal insulin, insulin efsitora alfa alpha later this year.”

In context

“mplications. Also this year, we are planning to initiate a Phase III program for Lepodiserin, our LPA-lowering siRNA therapy in cardiovascular disease. On Tirzepatide, we're looking forward to a number of additional key data readouts this year. Beyond SYNERGY-NASH, we expect to see results from the Phase III obstructive sleep apnea and Phase III heart failure studies this year. We note increased investor interest in the timing of SURPASS-CVOT, and we reiterate that we expect the data in 2025, notwithstanding the clinicaltrials.gov listing which will be updated soon to reflect our current assumptions based on event rate. By the end of 2024, we expect to have results of SURMOUNT 5, which is our head-to-head study of Tirzepatide compared to high-dose semaglutide in participants with obesity. We also expect the full Phase III program readout on our weekly basal insulin, insulin efsitora alfa alpha later this year. Moving to neuroscience. We're looking forward to FDA action and the potential launch of Erenumab in Q1 of this year, and we are progressing with regulatory reviews around the world. We've now launched a PT 217 blood-based diagnostic test, and we will continue to scale this throughout 2024. We'll also continue to partner with others in the field to ensure physicians have multiple tools to aid in timely and accurate diagnosis of Alzheimer's disease. In immunology, following the Mirikizumab positive Phase III data at Crohn's disease, we plan to submit to the FDA for this indication this year. Additionally, following the U.S. FDA complete response letter on Lebrikizumab, we expect regulatory action by the end of the year in the U.S. Finally, in oncology, as I mentioned before, we look forward”